Home / Fact sheets / Population fact sheet

Country fact sheet: Luxembourg

Population

- Total population: 582 014
- Female population: 289 646
- Male population: 292 368
The World Bank (2016)

Health Expenditure

- Total per capita (US$): 6 236.0
- Out-of-pocket (% of total expenditure on health): 10.6
World Health Organization (2015)

Human Development Index

- HDI: 0.898
- Category: Very high
UNDP Human Development Report (2015)

Geography

Life Expectancy at Birth

- Total population (years): 82.3
- Female population (years): 84.7
- Male population (years): 80.0
The World Bank (2016)

Cancer Burden

- Overall cancer incidence (rate per 100 000 persons per year): 309.3
- Overall cancer mortality (rate per 100 000 persons per year): 89.6
- Most common cancer site by incidence for females (rate per 100 000 persons per year): Breast (109.3)
- Most common cancer site by mortality for females (rate per 100 000 persons per year): Breast (15.8)
- Most common cancer site by incidence for males (rate per 100 000 persons per year): Prostate (78.8)
- Most common cancer site by mortality for males (rate per 100 000 persons per year): Lung (28.4)
- GLOBOCAN 2018 population fact sheet
GLOBOCAN (2018)

BREAST CANCER SCREENING PROGRAMME

Last updated year for qualitative data: 2016
Source of data: Report (EU Report 2017)
Last updated year for quantitative data: 2013
Source of data: Report (EU Report 2017)

Screening protocol

Year published/updated: No answer
Target age (min-max) and screening interval [months] for each test: Mammography
(50-69 years / [24 months] )

Programme status and organization

Dedicated person/team to coordinate the programme: Yes
Budget line for screening programme: Yes
Documented cancer screening policy: Yes
Nature of documentation of the policy: Official recommendation
Program introduction was preceded by a pilot: No answer
Year program was initiated: 1992
Screening tests provided free of charge: Yes
Diagnostic tests provided free of charge: Yes
Treatment services provided free of charge: No answer

Information system/Data collection

Data type collected by the programme: Individual
The information system collects data outside the program (opportunistic screening/private sector): No answer
Cancer screening registries covering the entire country/region: Yes
Cancer screening data is linked with Population-based cancer registry: Yes

Invitation to screening and further assessment

Method of identification of eligible individuals: From population data
Source of population data: Population register
Annual target for screening coverage: No answer
Invitations to eligible population: Yes, For the entire target population
Method of invitation: letter
Screen positive individuals actively invited for further assessment: Yes
Individuals with a precancer or cancer diagnosis actively contacted: No answer
Program collects data on the treatment of precancer/cancers: No answer

Programme monitoring and quality assurance (QA)

Documented standard operating procedure/policy for QA: Yes
Responsible person/team for QA: Yes
Documented performance indicators and their reference standards to assess the programme: Yes
Evaluation reports are prepared and published: Yes

Cancer Screening programme status

Nature of cancer screening programme: Population-based
Current status of implementation (applicable only for population-based programmes): Roll-out completed
Cancer screening programme population based for selected populations: No answer

Performance indicators

Target age and regional limitation if applicable: 50-69 years
Invitation coverage (%): 107.5
Examination coverage (%): 60.4
Participation rate (%): 56.6
Completeness of data related to screening results (%): 99.7
Completeness of data related to further assessment results (%): 97.9
Further assessment rate (%): 6.0
Further assessment participation rate (%): 97.9
Detection rate of CIS and invasive (x 1000): 6.39
Detection rate of invasive cancer (x 1000): 1.01
Positive predictive value of further assessment to detect CIS and invasive (%): 10.9
Proportion of total carcinomas which are CIS (%): 15.8
Benign surgical biopsy rate (x 1000): 0.45
More quantitative data (2013)



CERVICAL CANCER SCREENING PROGRAMME

Last updated year for qualitative data: 2016
Source of data: Report (EU Report 2017)
Last updated year for quantitative data: No data available currently
Source of data: No source

Screening protocol

Year published/updated: No answer
Target age (min-max) and screening interval [months] for each test: Cytology
(18- years / [12 months] )
Triaging test used: None
"screen and treat" included in the protocol: No answer

Programme status and organization

Dedicated person/team to coordinate the programme: No answer
Budget line for screening programme: No answer
Documented cancer screening policy: No
Nature of documentation of the policy: No answer
Program introduction was preceded by a pilot: No answer
Year program was initiated: No data submitted
Screening tests provided free of charge: No answer
Diagnostic tests provided free of charge: No answer
Treatment services provided free of charge: No answer

Information system/Data collection

Data type collected by the programme: Nothing
The information system collects data outside the program (opportunistic screening/private sector): No answer
Cancer screening registries covering the entire country/region: No answer
Cancer screening data is linked with population-based cancer registry: No answer

Invitation to screening and further assessment

Method of identification of eligible individuals: No answer
Source of population data: No answer
Annual target for screening coverage: No answer
Invitations to eligible population: No answer
Screening kit included with the invitation: No answer
Method of invitation: No answer
Screen positive individuals actively invited for further assessment: No answer
Individuals with a precancer or cancer diagnosis actively contacted: No answer
Program collects data on the treatment of precancer/cancers: No answer

Programme monitoring and quality assurance (QA)

Documented standard operating procedure/policy for QA: No answer
Responsible person/team for QA: No answer
Documented performance indicators and their reference standards to assess the programme: No answer
Evaluation reports are prepared and published: No answer

Cancer Screening programme status

Nature of cancer screening programme: Non population-based
Current status of implementation: No answer
Cancer screening programme population based for selected populations/regions: No answer

Performance indicators

Target age and regional limitation if applicable:
Invitation coverage (%):
Examination coverage (invitation cohort) (%):
Examination coverage (tests in the index-year) (%):
Participation rate (%):
Completeness of data related to screening test results (%):
Completeness of data related to further assessment results (%):
Colposcopy referral rate (%):
Colposcopy participation rate (%):
Detection rate of CIN2+ (x 1000):
Detection rate of CIN3+ (x 1000):
Positive Predictive Value of abnormal screening test to detect CIN2+ (x 1000):
Positive Predictive Value of CIN3+ (x 1000):



COLORECTAL CANCER SCREENING PROGRAMME

Last updated year for qualitative data: No data available currently
Source of data: Report (EU Report 2017)
Last updated year for quantitative data: No data available currently
Source of data: No source

Screening protocol

Year published/updated: No answer
Target age (min-max) and screening interval [months] for each test: FIT: (55-74 years / [24 months] )
Colonoscopy: (- years / [ months] )

Programme status and organization

Dedicated person/team to coordinate the programme: Yes
Budget line for screening programme: Yes
Documented cancer screening policy: Yes
Nature of documentation of the policy: Official recommendation
Program introduction was preceded by a pilot: No answer
Year program was initiated: 2016
Screening tests provided free of charge: Yes
Diagnostic tests provided free of charge: Yes
Treatment services provided free of charge: No answer

Information system/Data collection

Data type collected by the programme: Individual
The information system collects data outside the program (opportunistic screening/private sector): No answer
Cancer screening registries covering the entire country/region: Yes
Cancer screening data is linked with population-based cancer registry: Yes

Invitation to screening and further assessment

Method of identification of eligible individuals: From population data
Source of population data: Population register
Annual target for screening coverage: No answer
Invitations to eligible population: Yes, For the entire target population
Method of invitation: letter
Screen positive individuals actively invited for further assessment: Yes
Individuals with a precancer or cancer diagnosis actively contacted: No answer
Program collects data on the treatment of precancer/cancers: No answer

Programme monitoring and quality assurance (QA)

Documented standard operating procedure/policy for QA: No answer
Responsible person/team for QA: Yes
Documented performance indicators and their reference standards to assess the programme: No answer
Evaluation reports are prepared and published: Yes

Cancer Screening programme status

Nature of cancer screening programme: Population-based
Current status of implementation (applicable only for population-based programmes): Phased implementation
Cancer screening programme population based for selected populations: No answer

Performance indicators

FIT gFOBT sigmoidoscopy Colonoscopy
Target age and regional limitation if applicable:
Invitation coverage (%):
Examination coverage (%):
Participation rate (%):
Completeness of data related to screening results (%):
Completeness of data related to information about attendance to colonoscopy assessment (%):
Completeness of data related to histology result (%):
Screen positivity (indication for follow-up colonoscopy) rate (%) :
Follow-up colonoscopy participation rate (%):
Completion rate follow-up colonoscopy (%):
Detection rate of adenomas (x 1000):
Detection rate of advanced adenomas (x 1000):
Detection rate of colorectal cancers (x 1000):
Positive Predictive Value of further assessment to detect adenomas (%):
Positive Predictive Value of further assessment to detect advanced adenomas (%):
Positive Predictive Value of further assessment to detect colorectal cancers (%):